Medical technology company BD has announced plans to invest $19 billion in U.S. operations over the next several years, with more than $1 billion of the investment expected to go toward manufacturing in Nebraska.
The announcement comes as part of an agreement between BD and the Trump administration focused on expanding domestic production of medical supplies. BD says $3 billion of the overall investment will be directed toward strategic U.S. manufacturing sites. President Donald Trump said in a statement Monday that more than $1 billion of that investment will go to Nebraska.
BD operates facilities in both Broken Bow and Columbus, along with locations in several other states and Puerto Rico. The company’s announcement didn’t announce how the investment would be divided between facilities or what changes are planned specifically in Nebraska.
The company expects the investment to increase U.S. production of essential medical consumables by about 5 billion products annually, raising the share of those products supplied domestically by BD to roughly 80 percent.
BD also plans to manufacture all of its needles used in the United States domestically, using American made steel. The agreement provides BD with relief from future Section 232 tariffs on covered products and inputs, subject to the final scope of those tariffs and the company meeting agreed milestones.
The announcement follows separate expansion plans BD has already made in Nebraska. In January, a $110 million expansion in Columbus was announced that is expected to add about 120 jobs and expand production of prefillable syringes and cannulas.
BD says the final details of the new investment and the potential tariff relief will depend on future implementation of the agreement.
